Keyword: Bexsero

Merck's Gardasil 9 has been on an upward trajectory, but high global demand for the HPV shot has created a shortage for U.K. private clinics.

While only in the very early stages of its important Shingrix launch, GlaxoSmithKline turned in enough vaccine sales to lead the industry in 2017.

Serum Institute of India plans to launch four vaccines in the coming years for pneumococcal, HPV, meningococcal and dengue.

For three of the world’s top four vaccine companies, sales growth churned along in the second quarter as other areas struggled.

GlaxoSmithKline plans to explore MenB vaccine Bexsero's potential in preventing gonorrhea after a new study suggested plausible protection.

Analysts with Evaluate predict GlaxoSmithKline's Bexsero and Shingrix will quickly grow sales in the coming years.

Bexsero has been helping drive revenue growth for GSK, but now, with an EU approval, Pfizer’s Trumenba is set to challenge it in that lucrative market.

GSK's meningitis vaccine fueled vaccines growth that far outpaced the company's pharma unit, and a new plant and forthcoming launch could keep the momentum going.

Even as Pfizer’s vaccine outfit suffers a painful Prevnar 13 slowdown around the world, the group may soon get a boost in Europe.

With stellar vaccine sales for GlaxoSmithKline and Bexsero, GSK is building a $175 million plant in Germany to expand production of the meningococcal B shot.